Astimex Pharma has picked Recipharm as its development and manufacturing partner on a new drug.
Novasep is continuing to expand its contract manufacturing capabilities, now spending $38.8 million to build a commercial API plant in Mourenx, France.
Sanofi Pasteur MSD, a vaccine joint venture of Sanofi and Merck, recalled 16 batches--or 88%--of its Typhim Vi vaccine because of concerns about effectiveness.
Australia's Mayne Pharma has agreed to buy Metrics, a contract developer and manufacturer of niche drugs, in a deal worth up to $120 million.
Seeing a boost in demand for biologics, Olympus Biotech is offering CMO services out of its Lebanon, NH, plant.
As flu season approaches, vaccines companies are working against the odds to market their influenza vaccines. Last year, the overall U.S. vaccination rate was about 42%--a far cry from the target rates of 80% for people ages 6 months to 65 years and 90% for those older than 65.
Wisconsin CMO Cedarburg Hauser is expanding its API-production capabilities, responding to what it says is booming demand for drug components around the world.
Boehringer Ingelheim says it's coping with excess capacity in its CMO network, and will shut down one of its three API-producting plants in the U.S. as a result.
The CMO units of Merck KGaA and Boehringer Ingelheim are investing in single-use, disposable technolgies in their manufacturing processes, saying the move will help their clients get drugs on the market faster than traditional methods.
Catalent Pharma Solutions has teamed up with South Korea's CTC Bio to attract clients looking to market solid oral dose and controlled-release products in the U.S. and Europe.